Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical

The future frontier for hackers is synthetic biology.

Landmark scientific projects such as the Human Genome Project can encourage international cooperation and bring nations together. However, when security interests and defence research align with the prestige of a landmark project—international competition is all but assured. Synthetic biology is a scientific discipline less than a decade old, and the potential defence and security applications may create a new space race, this time between the USA and China.

The larger concern is not that this race may happen, but that if it does it will politicise and militarise an ethically sensitive area of the life sciences at a time when this frontier technology is critical to maintaining a sustainable world.

The Human Genome Project (HGP) cost about US$300 million (A$394 million), involved 20 international institutions and sequenced the human genome in just over a decade. The draft sequence was published in February 2001 and has driven economic, health and social benefits the world over for the last 15 years. To a very large extent this research project underpins the modern life sciences and is the equivalent of landing on the moon.

Continue reading “The Science of a New Space Race” | >

Micro-manufacturing is perfecting quality control.

Biology is the world’s greatest manufacturing platform, according to MIT spinout Ginkgo Bioworks.

The synthetic-biology startup is re-engineering yeast to act as tiny organic “factories” that produce chemicals for the flavor, fragrance, and food industries, with aims of making products more quickly, cheaply, and efficiently than traditional methods.

“We see biology as a transformative technology,” says Ginkgo co-founder Reshma Shetty PhD ’08, who co-invented the technology at MIT. “It is the most powerful and sophisticated manufacturing platform on the planet, able to self-assemble incredible structures at a scale that is far out of reach of the most cutting-edge human technology.”

Continue reading “MIT News: Hacking microbes” | >

A new tool to battle colon cancer.

Edible ginger-derived nano-lipids created from a specific population of ginger nanoparticles show promise for effectively targeting and delivering chemotherapeutic drugs used to treat colon cancer, according to a study by researchers at the Institute for Biomedical Sciences at Georgia State University, the Atlanta Veterans Affairs Medical Center and Wenzhou Medical University and Southwest University in China.

Colorectal cancer is the third most common cancer among men and women in the United States, and the second-leading cause of cancer-related deaths among men and women worldwide. The incidence of colorectal cancer has increased over the last few years, with about one million new cases diagnosed annually. Non-targeted chemotherapy is the most common therapeutic strategy available for colon cancer patients, but this treatment method is unable to distinguish between cancerous and healthy cells, leading to poor therapeutic effects on tumor cells and severe toxic side effects on healthy cells. Enabling chemotherapeutic drugs to target cancer cells would be a major development in the treatment of colon cancer.

In this study, the researchers isolated a specific nanoparticle population from edible ginger (GDNP 2) and reassembled their lipids, naturally occurring molecules that include fats, to form ginger-derived nano-lipids, also known as nanovectors. To achieve accurate targeting of tumor tissues, the researchers modified the nanovectors with folic acid to create FA-modified nanovectors (FA nanovectors). Folic acid shows high-affinity binding to the folate receptors that are highly expressed on many tumors and almost undetectable on non–tumor cells.

Continue reading “Nano-lipid Particles From Edible Ginger Could Improve Drug Delivery for Colon Cancer, Study Finds” | >

Very hopeful — Nano-based masks for a more comfortable radiation treatment.

BOSTON, Sept. 7, 2016 /PRNewswire/ — September 25–28, 2016 – Like every year, Orfit Industries will be present at the ASTRO Annual Meeting in the Boston Convention & Exhibition Center known to be the world’s most important meeting for the radiation oncology community, with more than 11,000 people attending each year. Orfit Industries invites customers, medical specialists and professionals to come to the Orfit booth (no. 2033) and try on the new generation of nano-based masks.

Compared to Efficast® masks used for head and neck immobilization, immobilization masks made from nano-enhanced thermoplastic sheets provide the patient with more comfort through a lower degree of shrinkage and therefore reduced pressure on the face during radiation therapy. The issue of mask tightness is a very common one as medication received during the radiation treatment phase may result in an increase in the volume of the patient.

In its efforts to provide a higher degree of patient comfort, Orfit Industries developed a nano-based thermoplastic material that results in thinner masks with less shrinkage. Orfit engineers have interwoven a natural material (nano clay) in the inner layers of the thermoplastic material, which resulted in a substantial improvement of its mechanical properties. Thermoplastics will shrink when they cool on the patient during the mask making process and therefore have an impact on comfort, in particular when the volume of the patient tends to increase in the course of treatment. In this context, the reduction of shrinkage by means of NANOR® is an important step forward as it provides the degree of comfort required to minimize patient movement during the delivery of the dose.

Read more

Silicon Valley, or the Greater Bay Area, is the 18th largest economy in the world, more than half the size of Canada’s economy and bigger than Switzerland, Saudi Arabia or Turkey. This is because the region has become the world leader in research and development of emerging technologies such as artificial intelligence, robotics, software and virtual reality.

“Software is eating the world,” said Silicon Valley investor Marc Andreessen famously in 2011. It was controversial but prescient.

Five years later, software-driven machines and drones perform surgery, write news stories, compose music, translate, analyze, wage war, guard, listen, speak and entertain. The world’s biggest box office hits — animated films such as “Frozen” or special effects in Hollywood blockbusters like “Star Wars” — are made using software.

Read more

In people with Alzheimer’s disease, a new investigational drug can dramatically reduce the amount of amyloid beta plaque, the tangled clumps of proteins that form in the brains of Alzheimer’s patients, according to a new early study of the drug.

The drug works by spurring the immune system to recognize and clear the plaques.

“We believe that’s a hint of efficacy,” study co-author Dr. Alfred Sandrock, a neurologist and an executive vice president at Biogen, said during a news briefing. “We believe that needs to be confirmed with further studies.” Biogen is the Cambridge, Massachusetts, company that funded the trial and applied to patent the drug. [10 Things You Didn’t Know About the Brain].

Read more

In a study published in Nature Medicine, researchers report that they have successfully coaxed stem cell-derived neurons to regenerate lost tissue in damaged corticospinal tracts of rats.

Stem cells are an amazing part of medical research. Because of their ability to become virtually any cell in the human body, they could hold the cure for many varied and grave diseases—from bones, to sight, to memory and thinking, stem cells could help us correct a host of conditions.

In fact, it seems that stem cells might be the key to repairing spinal cord injuries.

Read more